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Abstract
Typically, gene expression biomarkers are being discovered in course of high-throughput experiments, for example,
RNAseq or microarray profiling. Analytic pipelines that extract so-called signatures suffer from the “Dimensionality
curse": the number of genes expressed exceeds the number of patients we can enroll in the study and use to train
the discriminator algorithm. Hence, problems with the reproducibility of gene signatures are more common than
not; when the algorithm is executed using a different training set, the resulting diagnostic signature may turn out
to be completely different.
In this paper we propose an alternative novel approach which takes into account quantifiable expression levels of
all genes assayed. In our analysis, the cumulative gene expression pattern of an individual patient is represented as
a point in the multidimensional space formed by all gene expression profiles assayed in given system, where the
clusters of “normal samples” and “affected samples” and defined. The degree of separation of the given sample
from the space occupied by “normal samples” reflects the drift of the sample away from homeostasis in the course
of development of the pathophysiological process that underly the disease. The outlined approach was validated
using the publicly available glioma dataset deposited in Rembrandt and associated with survival data. Additionally,
the applicability of the distance analysis to the classification of non-malignant sampled was tested using psoriatic
lesions and non-lesional matched controls as a model.
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Introduction
The typical application of gene expression signatures for
diagnosis and prediction of the course of disease is based
upon an oversimplified understanding of the pathology.
According to this model, there is a gene or a set of genes
(say, a “gene expression program”) that is “responsible” for
a pathophysiological process within certain tissue, or a cell
type, that manifests itself on an organismal level as a dis-
ease. If we see this gene over- or underexpressed, or
observe a set of concerted changes in expression of a set
of genes, we can diagnose the disease. We can further use
the respective levels of the over- or underexpression to
predict the course of the disease.
While many diseases are well described by this model,
some–like many cancers– are not. Often we deal with a
system-wide changes of entire gene expression profile that
involve many cellular pathways and networks, some
changes are being related to the pathogenesis, and some
are of compensatory nature [1]. In the case of system-
wide changes, the sheer number of the genes to be exam-
ined prevents unambiguous determination of a group of
genes (using a more technical language, a linear combina-
tion of their expression levels) suitable as a diagnostic sig-
nature for the given disease. The problem is not with the
procedure per se, but with a typically limited number of
already diagnosed patients we could biopsy and enter into
the analysis as a training data set. As shown by simula-
tions in [2], the development of the robust gene signature
require enrollment of thousands patients, which is not fea-
sible (see also [3] for detailed discussion).
* Correspondence: abaranov@gmu.edu
1School of Systems Biology, George Mason University, David King Hall, MSN
3E1, Fairfax, VA, 22030, USA
Full list of author information is available at the end of the article
Veytsman et al. BMC Genomics 2014, 15(Suppl 12):S10
http://www.biomedcentral.com/1471-2164/15/S12/S10
© 2014 Veytsman et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
In a nutshell, the problem is that we are trying to profile
many different genes simultaneously. In a typical high-
throughput experiment assessing transcriptome, proteome
or metabolome, the number of available tissue samples is
much smaller than the number of variables [3]. This leads
to a high probability of spurious correlations. Indeed, even
if the probability for one gene expression level to show a
spurious correlation with the disease within the given data
set is as small as 10− 3, an analysis of data streaming from
this experiment with 4 × 104 genes will almost certainly
produce many false positives.
This problem is especially prominent in the analysis of
mRNA microarray or the RNAseq experiments. When dif-
ferent groups extract diagnostic signatures for the same
disease, the resultant sets of genes often have negligible
overlap. For example, the tests [4] and [5] for breast carci-
noma, having 76 genes and 70 genes correspondingly,
have only 3 genes in common. Even starting from the
same data set, one can get different “predictive” panels
with minimal overlap [6]. The difference in gene sets
extracted using different training sets is not limited to
individual genes. The pathways and networks that can be
built using independently obtained gene expression signa-
tures are also quite different [7]. These observations cast
substantial doubt at the biological relevance of the diag-
nostic approach that relies on gene signatures.
Expression levels for individual genes and other variables
quantified in high- throughput biological experiments are
commonly thought of as dimensions of the space on which
we are collecting information. Thus the problem outlined
above is known as the “curse of dimensionality” [8]. Briefly,
in highly dimensional models, the number of parameters
(dimensions) p is substantially larger than the sample size
n. This property of biological datasets makes the task of dis-
tinguishing the noise from the true biological signal quite
challenging, and it becomes close to impossible to obtain
consistent estimator procedures [9,10]. Hence there is a
need to develop integrative approaches, capable of combin-
ing data from multiple high-throughput experiments to
increase sample size [9,10] or statistically sound and robust
techniques to reduce the data to the most informative fea-
tures. As an example of the latter approach, we can try to
transform the entire dataset into a limited set of clusters
using hierarchical clustering [11]: starting from the defini-
tion of a distance between two tissue samples, we proceed
by regrouping individual expression profiles to obtain a
branched cluster tree. Unfortunately, hierarchical clustering
produces plausibly looking trees even when random data
points are entered [12]. Hence, an extensive data perturba-
tion by resampling is required for the validation of the
obtained clustering [13]. Moreover, unsupervised classifica-
tion techniques are far from being robust, as the inclusion
of a new patient typically modifies original clustering.
Another popular solution to the dimensionality curse
is to use a supervised approach that relies either on the
pre-selection of the feature-limiting steps or on pre-fil-
tering the data by the strength of an association of each
variable with clinical outcome, or associations between
variables [14,15]. Unfortunately, a majority of biological
data analysts try a variety of data processing techniques
before arriving at the final one that seems to be suitable
to the dataset in question. Therefore this kind of super-
vision is inherently biased.
In this paper we propose an alternative novel approach
based on the “distances” in the multidimensional space of
gene expression values. As a proof-of-principle, we show
that this approach produces surprisingly good results in
separation of normal and affected samples both for analy-
sis of human malignancies and for chronic progressive
conditions like psoriasis.
Multidimensional distances and clustering
A result of an expression experiment for a given sample
is a (very long) vector that may be represented as a
point in a multidimensional space. If we introduce a dis-
tance in this space, we can use the standard clustering
techniques [16] to classify the points.
There are several ways to define the distance between
two points, X = [x1, x2, ...] and Y = [y1, y2, ...] (see the dis-
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It takes all components of vectors equally and does
not account for any correlations between them. We can







where the averaging denoted by angular brackets is
taken over all vectors in the dataset. Then the scaled







In the gene expression experiments the absolute
values of the vectors are not relevant since the expres-
sions are arbitrarily normalized. Therefore, using a dis-
tance that does not take these values into account is
justified. A correlation distance, or Pearson distance, is
the one that has this property. It is defined as
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If we have enough data to calculate covariance matrix
S with the elements obtaining by the averaging over all






them we can use Mahalanobis distance
D2Mahalanobis = (X− Y)TS−1(X− Y) (6)
This distance takes into account all correlations in the
data. The problem with it is that to calculate correlation
matrix and its inverse, many data points, i.e. many
patients, are required.
Therefore, in the calculations below we use, as a rule,
Pearson distance (4). Note that since all components of
|X| and |Y| are non-negative, this distance is always
between 0 and 1.
Methods
To test for the practical usefulness of the distance-based
expression metrics we deployed the following strategy:
1 The datasets were selected from public MIAME-
compliant GEO repository http://www.ncbi.nlm.nih.
gov/geo/.
2 For each subset of the samples within data set
(normal tissues, affected tissues, etc.) we calculated
the coordinate for the center of the space defined by
points of all the vectors as the simple arithmetic
mean of all the samples in the subset.
3 For each point we calculated the distance to the
centers of all subsets.
4 The distances to one center r1 vs. the distance to
another center r2 were plotted.
In some datasets, three different subsets may be defined,
instead of two. In these cases, each point was associated
with three distances r1, r2 and r3, each plotted to the cen-
ter of the corresponding subset. In these cases we used
barycentric coordinates [17] in a equilateral triangle, with
the distance di from the vortex i proportional to
di =
ri
r1 + r2 + r3
(7)
Note that most programs dealing with barycentric
coordinates (for example, the popular package [18]) use a
different definition of the coordinate system, popular in
the analysis of ternary mixtures. With this definition the
distance to the vortex is proportional to Di = 1 − di. The










Expression profiles of primary tumors and their
metastases drift away from the homeostatic state
To test the hypothesis that the expression profiles of pri-
mary tumors and their metastases drift away from the
healthy, homeostatic state, the RNAseq dataset with GEO
Series accession number GSE46622 described in [19] was
downloaded and reanalyzed. This dataset was generated
using RNAseq profiling of matching normal, tumor and
metastasis tissues from eight colorectal cancer patients. In
the study, adaptor-clipped Illumina Genome Analyser IIx
reads were mapped to the human genome version
GRCh37 (hg19) using transcript models taken from
Ensemble v64 with TopHat followed by determination of
differential expression using the Cufflinks software bundle
and the cuffdiff with upper quartile normalization [19].
Accordingly we had three different subsets and three
different centers of clusters. These data may be pre-
sented either as the points within a 3d cube (Figure 1),
or as barycentric diagram (Figure 2). Both diagrams
show that normal samples are located relatively close to
the normal center, while metastatic and cancer clusters
are much less compact.
In a practical sense, one may be interested in how far
away given tumor sample departed from the center of the
space occupied by normal samples. This approach allows
one to draw a linear plot (Figure 3). Interestingly, not all
normal samples are clustered tightly around the center of
the normal space, at least one of them strays away into
the space area that doubts its normal origin. This obser-
vation may be explained by the fact that in this particular
dataset, all normal samples were derived from margins of
the colon tumors, therefore, the sample in question may
not be entirely normal. Of note, the distance-based
spread in primary tumors was even large than that in
metastasis derived from the same group of patients, sup-
porting the “metastatic dormancy” theory posing that a
disseminated tumor cell remains in a quiescent state at a
remote organ for years before its reactivation in response
to both an intrinsic program and a set of contextual cues
[20]. Metastatic reactivation does not require the tran-
scriptional profile be farther away from the normal center
than that of respective primary tumor. However, the rela-
tive distance may be related to the total number of cell
divisions passed from the onset of tumorigenesis; in the
metastatic site that remained dormant for a long time,
the number of cell divisions passed may be, in fact, lower
than that in the site of the primary tumor.
The drifting distances of tumor samples reflect the
degree of their relative malignancy
To prove this point, we downloaded data represented in
publicly available Repository for Molecular Brain Neoplasia
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Figure 1 Distances from cluster centers for colorectal cancer, 3D plot. Each sample is represented as a point in the three-dimensional
space defined by the distances to the normal, cancer, and metastatic center.
Figure 2 Distances from cluster centers for colorectal cancer, barycentric plot. Plot of the distances in barycentric coordinates.
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Data (Rembrandt) http://caintegrator.nci.nih.gov/
rembrandt/, which included data on 21 normal samples,
221 glioblastoma multiforme (GBMs), 145 astrocytomas,
66 oligodendrogliomas and 11 tumors of mixed origin.
The raw gene expression CEL files from Affymetrix
HGU133 Plus 2.0 arrays were normalized using the robust
multi-array average (RMA) method [10] with default para-
meters [21].
The plots reflecting the distances to the center of nor-
mal samples for all studied groups of samples are shown
on Figures 4 and 5. Similarly to the the pattern observed
using colorectal dataset normal samples were compacted
close to the normal center, while the majority of tumor
samples drifted away from norm. Glioblastoma multiforme
samples were, on average, located further from the center
of normal space than either astrocytomas (p = 3.1 × 10−6)
or oligodendrogliomas (p = 0.0033). In both astrocytomas
and oligodendrogliomas, the observed spreads of the dis-
tance values were quite large, possibly reflecting known
heterogeneity of these tumors [22,23].
Interestingly, patients survival were found to be nega-
tively correlated with the distance of the tumor expression
profile to the center of normal samples: the farther was
the expression profile from the homeostatic center defined
by normal samples, the shorter was the survival length for
the patient. The corresponding plot is shown on Figure 6
together with the linear fit. The fit results give p = 2 ×
10−9 and R2 = 0.09. This means that the dependence is sta-
tistically significant, but the degree of the drift away from
the center of the normal space explains only 9% of the
survival prognosis, while the remaining 91% is explained
by other factors, most likely, particular chromosomal rear-
rangements and mutations observed within the tumor
along with tumor location and other known determinants
of glioma prognosis [24].
Distance analysis is applicable to classification of samples
collected from patients with non-malignant chronic
disease
To illustrate an applicability of the gene expression dis-
tance analysis to the classification of samples collected
from patients with non-malignant chronic disease, we
selected psoriasis, an autoimmune disease mainly diag-
nosed through the visual inspection of the lesion skin by
experienced dermatologists. To analyze the properties of
gene expression profiles of lesional and non-lesional
Figure 3 Distances from the normal center for colorectal cancer. Plot of the distance to normal center for colorectal cancer and different
groups of samples.
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Figure 4 Distances from the center of normal samples for multiple cancers, part I. Boxes correspond to the second and third quartiles of the data.
Figure 5 Distances from the center of normal samples for multiple cancers, part II. Points represent individual samples.
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psoriatic skin samples from the same patient, two data-
sets were downloaded from GEO, GSE6710 [25] (N of
paired samples = 13) and GSE11903 [26] (N of paired
samples = 15). Both datasets were created using Affyme-
trix Human Genome U133A Array platform. As could
be seen on Figures 7 and 8, even without cross-normali-
zation, the distance metrics were able to cluster together
gene expression profiles obtained using two independent
non-lesional sample sets, while gene expression profiles
of lesion samples were somewhat removed from the
center of space occupied by non-lesional skin samples.
Discussion
To date, the quantification of the diagnostic and prog-
nostic biomarker molecules in the human serum and
tissues, including cancer specimens, remains the primary
means of enhancing the clinician’s ability to diagnose
the chronic condition. Importantly, with innumerable
molecular markers in development, the discovery of
novel standalone biomarkers with acceptable sensitivity
and specificity is an extremely rare event.
Here we challenge the biomarker paradigm by develop-
ing a distance measure that places each tissue sample by
its entire tissue-wide transcriptome profiles within the
space occupied by similarly obtained profiles of the
samples collected from the same individual or from indi-
viduals that do not have given chronic condition. We
hypothesize that as farther away individual sample drifts
from its homeostatic state defined as center of the space
occupied (defined) by a large number of reference (nor-
mal) samples, as farther away the respective tissue will be
from the well maintained, healthy state. In our study, we
used publicly available datasets, to develop easily inter-
pretable, composite measure that capable of integrating
high-throughput transcriptome profiles into comprehen-
sive, holistic metric describing the molecular homeostasis
within given sample.
The comprehensive distance measures account for
the intrinsic heterogeneity of human tumors that pla-
gues hight-throughput studies involving this type of
the biological material [27] and even for a heterogene-
ity of the cell types that comprise given tissue [28]. In
particular, the composite biomarker metric that we call
a distance metric, was validated using well-known
Rembrandt glioma dataset associated with survival
outcomes.
Importantly, proposed composite biomarker may be
suitable for a dynamic description of patients’ condition.
This novel concept allows one to depart from the classi-
cal two-bin prediction model (e.g. “bad prognosis/good
Figure 6 Dependence of the post-diagnosis survival on the distance to then normal center for multiple cancer. The line corresponds to
the fit y = 1.94 × 103 - 1.35 × 104x.
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Figure 7 Distances from the cluster centers for psoriasis data. Unfilled blue symbols correspond to uninvolved skin, filled red symbols
correspond to lesion skin.
Figure 8 Distances from the uninvolved center for psoriasis data. Unfilled blue symbols correspond to uninvolved skin, filled red symbols
correspond to lesion skin.
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prognosis”) as it produces a continuous prognosis
model, where each sample is located in the neighbor-
hood of other samples analyzed post-hoc and associated
with known survival. For each sample, this concept
quantitatively describes the degree of “the drift” from
the standardized phenotype that will reflect the depar-
ture of the body from homeostasis. In the concepts, the
effects of each personalized intervention could be evalu-
ated by comparing the distance metrics for samples col-
lected before the treatment and at multiple time-points
within the interventional treatment course.
If proven valid, this concept might be developed into a
novel type of integrative tests for the monitoring of the
disease progress and the prediction of disease outcomes.
The proposed distance analysis has a potential to
become versatile in its application as it is equally attri-
butable to gene expression profiles collected both by
microarrays and by RNA-seq platforms, as well as, pos-
sibly, to proteome and metabolome profiles.
There is no doubt that proposed computational
approach requires further development and optimiza-
tion, in particular, other types of correlation-based
metrics have to be tested for various kinds of multipara-
metric datasets that comprise simultaneously measured
analytes. Future studies should include an analysis of
longitudinal experiments that involve either various time
points in course of the therapeutic treatment that ulti-
mately results in the normalization of the pathological
condition, or gradual processes detrimental to experi-
mental system, for example, a development of insulin
resistance or an ageing.
Conclusion
The distance analysis of molecular portraits is robust
and versatile in its application as it is equally attributa-
ble to gene expression profiles collected by microarrays
and by RNA-seq. The distance-based continuous predic-
tive models depart from the classical two-bin prediction
model (e.g. “bad prognosis/good prognosis”) by placing
each sample in the neighborhood of other samples ana-
lyzed post-hoc and associated with known survival.
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